Biosecurity

ZMapp Ebola Drug Granted Fast Track Status by FDA

The U.S. Food and Drug Administration has granted ZMapp “Fast Track” designation for the treatment of Ebola virus disease.

The drug famously came into the public spotlight in 2014 after being administered on an emergency basis to Dr. Kent Brantly, a U.S. citizen infected with the Ebola virus in Liberia and evacuated to Emory University Hospital in Georgia.

The special designation is granted to drugs which are determined, based on nonclinical or clinical data, to have the potential to address an unmet medical need and that are intended to treat a serious condition.